Veerendra Munugalavadla

Acerta Pharma, AstraZeneca Group

BIOGRAPHY

Veerendra Munugalavadla has not added Biography.

If you are Veerendra Munugalavadla and would like to personalize this page please email our Author Liaison for assistance.

PUBLICATIONS

Acalabrutinib plus Obinutuzumab in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia.

Cancer discovery 03, 2020 | Pubmed ID: 31915195

Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial.

Lancet (London, England) 04, 2020 | Pubmed ID: 32305093

A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum-resistant metastatic urothelial cancer.

Cancer Oct, 2020 | Pubmed ID: 32757302

INSTITUTIONS

Acerta Pharma, AstraZeneca Group

JOVE ARTICLES

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis

Paola Marco-Casanova¹,

Natalia Lukashchuk¹,

Benedetta Lombardi¹,

Veerendra Munugalavadla²,

Melanie M. Frigault³,

Elizabeth A. Harrington¹,

J. Carl Barrett³,

Andrew J. Pierce¹

¹Translational Medicine, R&D Oncology, AstraZeneca,

², Acerta Pharma, AstraZeneca Group,

³Translational Medicine, R&D Oncology, AstraZeneca

Medicine

Privacy

Policies

Recommend to library

JoVE NEWSLETTERS

Research

JoVE Journal
Methods Collections
JoVE Encyclopedia of Experiments
Archive

Education

JoVE Core
JoVE Business
JoVE Science Education
JoVE Lab Manual
Faculty Resource Center
Faculty Site

Authors

Overview
Publishing Process
Editorial Board
Scope and Policies
Peer Review
FAQ
Submit

Librarians

Overview
Testimonials
Subscriptions
Access
Resources
Library Advisory Board
FAQ

ABOUT JoVE

Overview
Leadership
Blog
JoVE Help Center